Catalyst
Slingshot members are tracking this event:
Assuming the Phase 3 trials are successful, Palatin will file a New Drug Application for Bremelanotide in early 2018
- Source Link:
- http://www.irdirect.net/prviewer/release/id/2275464
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PTN | Community voting in process | |||||
Additional Information
Top-line results of the Phase 3 trials are on target for release in the third quarter of calendar 2016. Assuming the Phase 3 trials are successful, Palatin will file a New Drug Application in the first half of calendar 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 26, 2018
Occurred Source:
http://www.irdirect.net/prviewer/release/id/3013776
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nda, Bremelanotide
